JMP Securities Downgrades Optimer Pharmaceuticals (OPTR) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- AXT-Tongmei signs 3-year wafer supply deal with Coherent
Optimer Pharmaceuticals (OPTR) Posts Q2 Profit of $0.02/Sh
February 28, 2013 4:29 PM ESTOptimer Pharmaceuticals (NASDAQ: OPTR) reported Q4 EPS of $0.02, which may not compare to the estimate of ($0.38). Revenue for the quarter came in at $19.5 million versus the consensus estimate of $18.05 million.
"2012 was an exciting year for Optimer. DIFICID is now available in over a... More
